“Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of the Company's product candidates or compromise its ability to conduct its business or obtain regulatory approvals for the Company's product candidates.”
So what they’re saying is that it’s OUR fault the company has failed to market their “homerun” platform, and that small potatoes like us keep them from persuading big pharma or other entities that their program works. Not to mention the failure of tt-034, dropping programs left and right, failure to communicate frequently and transparently with shareholders, failing to meet timelines, and lack of share price appreciation despite CEO shakeup, Nant involvement, Axovant collaboration, and no big pharma collaboration on HBV.
